Posted by Michael Wonder on 29 Oct 2020
reVision Therapeutics announces US FDA grant of rare paediatric disease and orphan drug designation for REV-0100 for the treatment of Stargardt disease
28 October 2020 - reVision Therapeutics today announced that the US FDA has granted the Company's request to designate REV-0100 as an orphan drug and a rare paediatric disease drug for the treatment of Stargardt disease.
Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options.
